Engineering organic-organic and organic-inorganic nanohybrids for Drug Delivery

Q2 Pharmacology, Toxicology and Pharmaceutics

OpenNano Pub Date : 2026-05-01 Epub Date: 2026-04-28 DOI:10.1016/j.onano.2026.100305

Valentina Pacciani , Deborah Bonavolontà , Jacopo Cardellini , Lucrezia Caselli , Arianna Balestri , Debora Berti

{"title":"Engineering organic-organic and organic-inorganic nanohybrids for Drug Delivery","authors":"Valentina Pacciani , Deborah Bonavolontà , Jacopo Cardellini , Lucrezia Caselli , Arianna Balestri , Debora Berti","doi":"10.1016/j.onano.2026.100305","DOIUrl":null,"url":null,"abstract":"<div><div>Hybrid nanoparticles (HNPs) are emerging as cutting-edge materials in nanomedicine, offering unique opportunities for drug delivery, diagnostic imaging, and therapeutics. By harnessing interactions between organic or inorganic components, these systems achieve precise control over size, surface, and functional properties. The synergy between different building blocks enables enhanced biocompatibility, targeted delivery, and stimuli-responsive functions that are challenging to achieve with single-component systems. This review highlights the state of the art in organic–organic and organic–inorganic nanohybrids, focusing on recent advances for drug delivery applications. Examples include organic-organic hybrids combining lipids, polymers, and biological constituents, <em>e.g.</em>, extracellular vesicle- or cell membranes-derived components, as well as inorganic NPs hybridized with polymers, peptides, or lipids. We further discuss current challenges and future perspectives in the field, including hybrids that are responsive to internal or external triggers, which hold significant promise for advancing personalized medicine and translating nanomedicine innovations into the clinic.</div></div>","PeriodicalId":37785,"journal":{"name":"OpenNano","volume":"29 ","pages":"Article 100305"},"PeriodicalIF":0.0000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OpenNano","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352952026000253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Hybrid nanoparticles (HNPs) are emerging as cutting-edge materials in nanomedicine, offering unique opportunities for drug delivery, diagnostic imaging, and therapeutics. By harnessing interactions between organic or inorganic components, these systems achieve precise control over size, surface, and functional properties. The synergy between different building blocks enables enhanced biocompatibility, targeted delivery, and stimuli-responsive functions that are challenging to achieve with single-component systems. This review highlights the state of the art in organic–organic and organic–inorganic nanohybrids, focusing on recent advances for drug delivery applications. Examples include organic-organic hybrids combining lipids, polymers, and biological constituents, e.g., extracellular vesicle- or cell membranes-derived components, as well as inorganic NPs hybridized with polymers, peptides, or lipids. We further discuss current challenges and future perspectives in the field, including hybrids that are responsive to internal or external triggers, which hold significant promise for advancing personalized medicine and translating nanomedicine innovations into the clinic.

查看原文本刊更多论文

用于药物传递的工程有机-有机和有机-无机纳米杂化体

混合纳米颗粒（HNPs）正在成为纳米医学的前沿材料，为药物输送、诊断成像和治疗提供了独特的机会。通过利用有机或无机组分之间的相互作用，这些系统实现了对尺寸、表面和功能特性的精确控制。不同构建模块之间的协同作用增强了生物相容性、靶向递送和刺激响应功能，这是单组分系统难以实现的。本文综述了有机-有机和有机-无机纳米杂化材料的研究现状，重点介绍了其在药物传递应用方面的最新进展。示例包括结合脂质、聚合物和生物成分的有机-有机杂化物，例如，细胞外囊泡或细胞膜衍生的成分，以及与聚合物、肽或脂质杂交的无机NPs。我们进一步讨论了该领域当前的挑战和未来的前景，包括对内部或外部触发反应的杂交体，这对推进个性化医疗和将纳米医学创新转化为临床具有重要的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

OpenNano Medicine-Pharmacology (medical)

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

50 days

期刊介绍： OpenNano is an internationally peer-reviewed and open access journal publishing high-quality review articles and original research papers on the burgeoning area of nanopharmaceutics and nanosized delivery systems for drugs, genes, and imaging agents. The Journal publishes basic, translational and clinical research as well as methodological papers and aims to bring together chemists, biochemists, cell biologists, material scientists, pharmaceutical scientists, pharmacologists, clinicians and all others working in this exciting and challenging area.